Strides Pharma receives US FDA approval for prednisone tablets

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Strides Pharma Science has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for prednisone tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (FDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co. (Pharmacia).

According to IQVIA MAT December 2020 data, the US market for prednisone tablets USP, 10 mg and 20 mg is approximately US$ 60 million. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with US FDA of which 98 ANDAs have been approved and 29 are pending approval.

Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication. It is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

Bengaluru-based Strides, mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The company’s global manufacturing sites are located in India: Chennai, Puducherry and two in Bengaluru , Singapore, Italy: Milan, Kenya: Nairobi and the United States : Florida. It focusses on “difficult to manufacture” products that are sold in over 100 countries.

About Prednisone Tablets Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication. It is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

About Strides Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries.

Latest stories

Related stories

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Trump To Roll-Out 340B Drugs Discount Program in 2026

The Trump administration is going to pilot a voluntary...

60-Day Window by Trump for Firms to Lower Their Drug Prices

President Donald Trump of the USA has sent letters...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back